Martin Quinn - NuCana PLC Company Secretary
| NCNA Stock | USD 1.26 0.04 3.08% |
Executive
Martin Quinn is Company Secretary of NuCana PLC
| Address | 3 Lochside Way, Edinburgh, United Kingdom, EH12 9DT |
| Phone | 44 13 1357 1111 |
| Web | https://www.nucana.com |
NuCana PLC Management Efficiency
The company has return on total asset (ROA) of (0.6843) % which means that it has lost $0.6843 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8077) %, meaning that it created substantial loss on money invested by shareholders. NuCana PLC's management efficiency ratios could be used to measure how well NuCana PLC manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.02. The current year's Return On Capital Employed is expected to grow to -2.06. At present, NuCana PLC's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 2.6 M, whereas Total Assets are forecasted to decline to about 26.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marie Lindholm | Silence Therapeutics PLC | N/A | |
| MD JD | Cidara Therapeutics | N/A | |
| Steven RPh | Vincerx Pharma | 63 | |
| Shelly Pinto | Alx Oncology Holdings | 47 | |
| Catherine Thorpe | Applied Therapeutics | 60 | |
| Alexander MBA | Vincerx Pharma | 45 | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Allison Dillon | Alx Oncology Holdings | N/A | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Eric Groen | Rani Therapeutics Holdings | 53 | |
| Shelly CPA | Alx Oncology Holdings | 48 | |
| Michael Chang | Alx Oncology Holdings | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Leiv Lea | Corvus Pharmaceuticals | 70 | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Alireza Javadi | Rani Therapeutics Holdings | N/A | |
| Jim MBA | Cidara Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.81 | ||||
| Return On Asset | -0.68 |
NuCana PLC Leadership Team
Elected by the shareholders, the NuCana PLC's board of directors comprises two types of representatives: NuCana PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NuCana. The board's role is to monitor NuCana PLC's management team and ensure that shareholders' interests are well served. NuCana PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NuCana PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Harrison, Head Medicine | ||
| Gordon Kennovin, Senior Development | ||
| MD FACOG, Chief Officer | ||
| Stuart Grant, Senior Affairs | ||
| Donald Munoz, Chief Officer | ||
| Hugh Griffith, CEO, Founder, Director | ||
| Theresa Bruce, Senior Operations | ||
| Elisabeth Oelmann, Senior Development | ||
| JohnPaul Gallivan, Senior Management | ||
| FRCS MD, Chief Officer | ||
| Martin Quinn, Company Secretary |
NuCana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NuCana PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.81 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | (9.19 M) | ||||
| Shares Outstanding | 3.93 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 11.81 % | ||||
| Number Of Shares Shorted | 63.1 K | ||||
| Price To Earning | (7.52) X | ||||
| Price To Book | 0.90 X | ||||
| EBITDA | (28.89 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NuCana PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NuCana PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nucana Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nucana Plc Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NuCana PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade NuCana Stock refer to our How to Trade NuCana Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NuCana PLC. If investors know NuCana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NuCana PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.92) | Return On Assets (0.68) | Return On Equity (1.81) |
The market value of NuCana PLC is measured differently than its book value, which is the value of NuCana that is recorded on the company's balance sheet. Investors also form their own opinion of NuCana PLC's value that differs from its market value or its book value, called intrinsic value, which is NuCana PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NuCana PLC's market value can be influenced by many factors that don't directly affect NuCana PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NuCana PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if NuCana PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NuCana PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.